Close Menu

NEW YORK (GenomeWeb) –  Belgian molecular diagnostics firm Biocartis announced on Saturday that it has signed a master development and commercialization agreement with Gilead Sciences subsidiary Kite to develop molecular-based assays on its Idylla platform that support Kite's therapies.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.